We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Prothena (PRTA) Stock Is Up So Far This Month
Read MoreHide Full Article
Shares of Prothena Corporation (PRTA - Free Report) have surged 74.9% in the month so far compared with the industry's growth of 3.4%.
Image Source: Zacks Investment Research
Most of the upside came after the FDA approval of Biogen’s (BIIB - Free Report) Alzheimer's disease (AD) drug, Aduhelm. On Jun 7, 2021, Biogen and partner Eisai won the FDA approval for Aduhelm (aducanumab-avwa) as the first and only AD treatment, after a few setbacks.
The approval has brought the spotlight on other companies as well who are developing drugs for AD and investors are optimistic about the prospects of these pipeline candidates.
Prothena’s PRX005 is being evaluated for the treatment of AD. The candidate is an investigational antibody that targets tau, a protein implicated in diseases including AD, frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE) and other tauopathies.
Preclinical data showed that targeting an epitope within the microtubule binding region (MTBR) of tau with PRX005 resulted in superior attributes for the potential treatment of AD. PRX005 demonstrated significant inhibition of cell-to-cell transmission and neuronal internalization in vitro and in vivo, and slowed pathological progression in a tau transgenic mouse model. An Investigational New Drug (IND) application for the same is expected by the third quarter. PRX005 is being developed as part of the company’s global neuroscience collaboration with Bristol Myers (BMY - Free Report) .
The company has another candidate, PRX012, which is a potential treatment for AD. The candidate is a high-affinity monoclonal antibody targeting a key epitope within the N-terminus of Aβ. An IND for the same is expected by the first quarter of 2022.
The approval of Biogen’s AD drug has raised hopes for these candidates as well.
While the candidates hold promise, given their superior mechanism of action, they still have a long way to go and are a few years away from approval. We note that Prothena had earlier discontinued the development of NEOD001, an investigational antibody that was being evaluated for the treatment of AL amyloidosis. Hence, any pipeline setback will adversely impact the prospects.
Meanwhile, another company, Eli Lilly (LLY - Free Report) , too saw an increase in its share price lately on the prospects of its AD candidate, donanemab.
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Image: Bigstock
Here's Why Prothena (PRTA) Stock Is Up So Far This Month
Shares of Prothena Corporation (PRTA - Free Report) have surged 74.9% in the month so far compared with the industry's growth of 3.4%.
Most of the upside came after the FDA approval of Biogen’s (BIIB - Free Report) Alzheimer's disease (AD) drug, Aduhelm. On Jun 7, 2021, Biogen and partner Eisai won the FDA approval for Aduhelm (aducanumab-avwa) as the first and only AD treatment, after a few setbacks.
The approval has brought the spotlight on other companies as well who are developing drugs for AD and investors are optimistic about the prospects of these pipeline candidates.
Prothena’s PRX005 is being evaluated for the treatment of AD. The candidate is an investigational antibody that targets tau, a protein implicated in diseases including AD, frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE) and other tauopathies.
Preclinical data showed that targeting an epitope within the microtubule binding region (MTBR) of tau with PRX005 resulted in superior attributes for the potential treatment of AD. PRX005 demonstrated significant inhibition of cell-to-cell transmission and neuronal internalization in vitro and in vivo, and slowed pathological progression in a tau transgenic mouse model. An Investigational New Drug (IND) application for the same is expected by the third quarter. PRX005 is being developed as part of the company’s global neuroscience collaboration with Bristol Myers (BMY - Free Report) .
The company has another candidate, PRX012, which is a potential treatment for AD. The candidate is a high-affinity monoclonal antibody targeting a key epitope within the N-terminus of Aβ. An IND for the same is expected by the first quarter of 2022.
The approval of Biogen’s AD drug has raised hopes for these candidates as well.
While the candidates hold promise, given their superior mechanism of action, they still have a long way to go and are a few years away from approval. We note that Prothena had earlier discontinued the development of NEOD001, an investigational antibody that was being evaluated for the treatment of AL amyloidosis. Hence, any pipeline setback will adversely impact the prospects.
Meanwhile, another company, Eli Lilly (LLY - Free Report) , too saw an increase in its share price lately on the prospects of its AD candidate, donanemab.
Prothena currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>